Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Cost of Revenue (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cost of Revenue for 8 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 73.55% to $12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.5 million, a 56.26% decrease, with the full-year FY2025 number at $39.5 million, down 37.54% from a year prior.
  • Cost of Revenue was $12.5 million for Q4 2025 at Akebia Therapeutics, up from $9.4 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $74.7 million in Q4 2021 to a low of -$11.1 million in Q3 2021.
  • A 5-year average of $20.7 million and a median of $13.3 million in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 136.54% in 2021, then surged 390.91% in 2024.
  • Akebia Therapeutics' Cost of Revenue stood at $74.7 million in 2021, then plummeted by 68.39% to $23.6 million in 2022, then crashed by 59.09% to $9.7 million in 2023, then surged by 390.91% to $47.4 million in 2024, then plummeted by 73.55% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cost of Revenue are $12.5 million (Q4 2025), $9.4 million (Q3 2025), and $9.9 million (Q2 2025).